Hillstream BioPharma, Inc. (HILS)

0.2305 +0.0062 (+2.76%) At close: 03:59PM EDT

Hillstream BioPharma, Inc.

1200 Route 22 East
Suite 2000
Bridgewater, NJ 08807
United States
908 955 3140
https://www.hillstreambio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 1

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Randy D. Milby MBA	Pres, Chairman & CEO	471.94k	N/A	1954
Mr. Sireesh Appajosyula Pharm.D.	COO & Director	64.96k	N/A	1976
Mr. Thomas P. Hess CPA, MBA	Chief Financial Officer	N/A	N/A	1964

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) and targeted immuno-oncology novel biologics for the treatment drug resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-3215, an anti-HER2 monoclonal antibody candidate; and HSB-1940, a Quatrabody that is a proprietary IO biologic in development targeting PD-1. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.

Corporate governance

Hillstream BioPharma, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.